ArticleCureus2025
Evaluating the S100β, GFAP, IL-6, and Oxidative Stress Markers in Traumatic Brain Injury.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Traumatic brain injury (TBI) is a leading cause of neurological morbidity and mortality worldwide. Secondary injury mechanisms such as neuroinflammation and oxidative stress play a pivotal role in the progression of neuronal damage. Biomarkers, including S100β, glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), and oxidative stress parameters, can reflect the severity and progression of TBI, and their evaluation may assist in clinical decision-making. Objective This study aims to evaluate the serum levels of S100β, GFAP, IL-6, and oxidative stress markers (malondialdehyde (MDA), superoxide dismutase (SOD), and catalase) in patients with TBI compared to healthy controls. Methods This case-control study was conducted at The University of Lahore from July to December 2024. A total of 96 participants were enrolled, including 48 TBI patients and 48 age- and sex-matched healthy controls. Blood samples were collected within 24 hours of injury in TBI patients. Serum concentrations of S100β, GFAP, and IL-6 were measured using ELISA (enzyme-linked immunosorbent assay), while MDA, SOD, and catalase levels were assessed using standard biochemical assays. Data were analyzed using IBM SPSS Statistics for Windows, Version 26 (Released 2019; IBM Corp., Armonk, New York). Independent sample t-tests were used for group comparisons, and Pearson's correlation was applied to examine biomarker relationships. Results TBI patients exhibited significantly higher serum levels of S100β (1.92 ± 0.46 vs. 0.61 ± 0.18 ng/mL), GFAP (3.45 ± 0.71 vs. 1.12 ± 0.33 ng/mL), IL-6 (82.6 ± 18.4 vs. 19.5 ± 7.6 pg/mL), and MDA (5.12 ± 1.03 vs. 2.23 ± 0.66 µmol/L) compared to controls (p < 0.001 for all). SOD and catalase activities were significantly reduced in TBI patients (p < 0.001). S100β and GFAP correlated positively with IL-6 and MDA and negatively with SOD and catalase. Conclusion TBI is associated with elevated neural injury, inflammation, and oxidative stress biomarkers. These findings highlight the diagnostic and prognostic potential of these markers in TBI management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.